Ventyx Biosciences, Inc.

Ventyx Biosciences, Inc. to be Acquired by Eli Lilly for $14.00 Per Share: An 8-K Summary

Ventyx Biosciences, Inc. (VTYX) is making headlines: pharmaceutical giant Eli Lilly and Company is acquiring the company in an all-cash deal. This significant move transforms Ventyx from an independent public company into a wholly-owned subsidiary of Lilly, fundamentally reshaping its future.

Here's a breakdown of what happened, why it matters, and what investors should know, based on the official company filing on February 23, 2026:

The Acquisition Details

• What's Happening: Eli Lilly and Company will acquire Ventyx Biosciences, Inc. Ventyx shareholders will receive cash for each share they own.
• The Price: Each Ventyx share (VTYX) will convert into $14.00 in cash. Although the filing did not specify the total transaction value, this price represents a substantial premium over Ventyx's recent market valuation.
• Agreement Date: The definitive merger agreement was signed on January 7, 2026.
• Filing Date: Ventyx officially disclosed this detailed update in an 8-K filing on February 23, 2026.

Why This Acquisition? Lilly's Strategic Move

Eli Lilly, a global pharmaceutical leader, is acquiring Ventyx to strengthen its pipeline, especially in immunology and metabolic diseases.

• Promising Pipeline: Lilly's interest primarily stems from Ventyx's lead drug candidates:
  • VTX3232: This NLRP3 inhibitor showed positive Phase 2 study results on October 22, 2025, for obese individuals with cardiovascular risk factors. Ventyx is also exploring it for Parkinson's disease. NLRP3 inhibitors target a key inflammatory pathway, making them attractive for a range of conditions.
  • VTX2735: Another NLRP3 inhibitor, VTX2735, is under development for recurrent pericarditis and other inflammatory conditions.
• Competitive Process: Ventyx had previously discussed potential partnerships or deals with 16 other biopharmaceutical companies, highlighting strong market interest in its assets.
• Premium Valuation: Lilly's offer of $14.00 per share represents a significant premium. Financial advisors had valued Ventyx's standalone worth, even with potential partnerships, between $9.00 and $10.60 per share. This indicates Lilly sees substantial strategic value and future potential in Ventyx's programs.

Impact and Implications for Investors

This acquisition fundamentally reshapes the investment landscape for Ventyx shareholders:

• Guaranteed Cash Payout: Shareholders are guaranteed a fixed cash payout of $14.00 per share when the deal closes.
• Loss of Independent Upside: However, this certainty means shareholders will miss out on potential future upside if Ventyx's drugs achieved blockbuster status as an independent company. Investors will no longer participate in the long-term growth or success of Ventyx's pipeline.
• Stock Trading: Ventyx's stock (VTYX) will likely trade very close to $14.00 per share until the merger officially closes. Once the merger closes, Nasdaq will delist VTYX, and it will no longer trade publicly.
• Consider Your Options: If you own VTYX, you have two options: sell your shares on the open market now (likely near $14.00) or hold them until the merger closes to automatically receive the $14.00 cash.

What Happens Next? Key Milestones and Risks

While the merger is progressing, a few steps remain before its finalization:

• Regulatory Clearance: A significant hurdle was quickly cleared: the U.S. government granted antitrust approval (under the Hart-Scott-Rodino Act) on February 11, 2026. This eliminates a major potential roadblock.
• Remaining Conditions: The merger still requires standard closing conditions, including approval from Ventyx's shareholders.
• Expected Closing Date: The filing does not specify an expected closing date, but such transactions typically close within a few months after regulatory and shareholder approvals.
• Legal Challenges: Two Ventyx stockholders have filed lawsuits, alleging misleading information in the company's merger documents. Ventyx asserts these claims lack merit. While common in mergers, such lawsuits could cause delays and incur legal costs, though they rarely derail a definitive deal once regulatory approvals are in place.

Broader Implications

• For Ventyx: Ventyx will cease to exist as an independent entity, integrating its operations, employees, and pipeline into Eli Lilly.
• For the Pipeline: Ventyx's experimental drugs, particularly VTX3232 and VTX2735, will now benefit from Lilly's extensive resources, research capabilities, and global reach. This could accelerate their development and market access.
• For Employees: While specific employment agreements for Ventyx's executive officers remain under discussion, employees will likely transition into roles within Eli Lilly. However, some organizational changes are typical in acquisitions.
• For Patients: Patients who could benefit from Ventyx's innovative treatments may see faster development and broader availability of these potential therapies under Lilly's stewardship.